Biomarin Pharmaceutical (FRA:BM8) Ending Cash Position : €687 Mil (As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Ending Cash Position?

Biomarin Pharmaceutical's Ending Cash Position for the quarter that ended in Mar. 2024 was €687 Mil.

Biomarin Pharmaceutical's quarterly Ending Cash Position declined from Sep. 2023 (€736 Mil) to Dec. 2023 (€692 Mil) and declined from Dec. 2023 (€692 Mil) to Mar. 2024 (€687 Mil).

Biomarin Pharmaceutical's annual Ending Cash Position increased from Dec. 2021 (€520 Mil) to Dec. 2022 (€684 Mil) and increased from Dec. 2022 (€684 Mil) to Dec. 2023 (€692 Mil).

Biomarin Pharmaceutical Ending Cash Position Historical Data

The historical data trend for Biomarin Pharmaceutical's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Ending Cash Position Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

393.70

533.61

519.74

683.96

692.45

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															541.79	640.91	735.93	692.45	687.24

Biomarin Pharmaceutical Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Biomarin Pharmaceutical's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	664.395	+	28.056
	=	692

Biomarin Pharmaceutical's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	694.717	+	-7.481
	=	687

Biomarin Pharmaceutical Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (FRA:BM8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (FRA:BM8) Headlines

No Headlines